MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Sony to deal $760m stake back to Olympus

Sony to deal $760m stake back to Olympus

By

Olympus, SonySony (TYO:6758) will reportedly sell its 5% stake in Olympus (TYO:7733) back to the company for nearly $760 million.

The deal for Sony’s 68.9-million-share stake is worth ¥80.4 billion, or about $756.7 million, Reuters reported. Hedge fund Third Point, run by activist investor Daniel Loeb, had called for Sony to divest its Olympus shares, although a Sony spokeswoman told the wire service that the sale wasn’t made in reaction to any demand by shareholders. Sony is still reviewing Third Point’s proposals, the spokeswoman said.

Sony bought an 11% stake in Olympus for $640 million in 2012, forming Sony Olympus Medical Solutions to develop high-definition surgical endoscopes and microscopes.

The company said it decided to sell “considering that the initial purpose of the capital alliance to establish collaboration between Sony and Olympus has been accomplished and after reviewing the rationale for owning the Olympus shares,” according to Reuters.

SNE shares were flat at $56.69 apiece today in late morning trading in New York; the stock closed up 2.3% at ¥6,042.00 per share in Tokyo. Olympus shares jumped 3.6% to $11.63 each in New York, after closing up 6.8% at ¥1,244.00 in Tokyo.

($1 = ¥106.232)

In case you missed it

RSS From Medical Design & Outsourcing

  • Keep the end in mind when choosing a medtech partner
    There are five general categories of medtech vendor partners. If the end is apparent in the beginning, the correct type of partner will be more apparent. Jim Reed, Minnetronix Medical Stephen Covey gave the business world this mantra in one of his bestsellers: “Start with the end in mind.” Whether they didn’t read the book… […]
  • Orthofix launches Fiberfuse Strip bone graft
    Orthofix (NSDQ:OFIX) today announced that it has launched its FiberFuse Strip bone graft in the U.S. Lewisville, Texas–based Orthofix designed the FiberFuse Strip to be a preformed bone-graft strip for posterior cervical, posterior lumbar and degenerative spinal procedures. FiberFuse Strip is 100% bone and has a unique mixture of mineralized cancellous and demineralized cortical bone with… […]
  • Thermo Fisher Scientific beats The Street in Q2 results
    Thermo Fisher Scientific (NYSE:TMO) today posted second-quarter results that beat the overall consensus on Wall Street. The Waltham, Mass.–based company reported profits of $1.8 billion, or $4.61 per share, on sales of $9.3 billion for the three months ended July 1, 2021, for a bottom-line gain of 58.1% on sales growth of 34.1% compared with… […]
  • Choosing the Right Rubber Material and Process for Your Medical Parts
    When it’s time to design and develop a new medical device that calls for an elastomer component, there are a number of material options and manufacturing processes to consider. The long list of material properties impacting performance includes your prospective polymer’s end-use environment, chemical compatibility, hardness, compression set, tensile properties and manufacturability — to name… […]
  • 3M’s healthcare segment registers growth in Street-beating Q2
    3M (NYSE:MMM) reported second-quarter results that beat the consensus forecast — with the company’s healthcare segment showing especially robust growth. The St. Paul, Minn.–based company posted profits of $1.5 billion, or $2.59 per share, on sales of $9 billion for the three months ended June 30, 2021, for a 16.7% bottom-line gain on sales growth of… […]
  • Evren Technologies earbud PTSD treatment device nabs FDA breakthrough device designation
    Evren Technologies this week announced that it received FDA breakthrough device designation for its Phoenix earbud device that treats PTSD. Gainesville, Fla.-based Evren Technologies designed the Phoenix device as a discreet earbud design that delivers transcutaneous auricular vagal nerve stimulation in a closed-loop system. It can be paired with the company’s PTSD symptom tracking app… […]
  • BD acquires resorbable polymer maker Tepha
    BD (NYSE:BDX) today announced that it has acquired resorbable polymer technology maker Tepha for an undisclosed amount. Franklin Lakes, N.J.–based BD said that it will use Lexington, Mass.–based Tepha’s resorbable polymer technology to accelerate growth of the company’s surgical mesh for soft tissue repair, reconstruction and regeneration. Tepha’s GalaFlex portfolio is also included in the acquisition.… […]
  • LifeSignals remote patient monitor wins FDA clearance
    LifeSignals today announced that it has received FDA 510(k) clearance for its LX1550 multi-parameter remote monitoring platform. Fremont, Calif.–based LifeSignals designed the LX1550 to continuously collect patient physiological data from home and in healthcare settings. The platform has a single-use wearable multi-parameter biosensor that records electrocardiography (ECG), heart rate, respiration rate, skin temperature and body… […]
  • Blackrock Neurotech and ClearPoint Neuro want to automate brain implant surgeries
    ClearPoint Neuro (NSDQ:CLPT) announced an agreement with Blackrock Neurotech to develop automated technologies for brain implant surgeries. The partnership will seek to develop an automated surgical solution for implanting brain-computer interfaces (BCIs) into patients with neurological disorders — including from paralysis, ALS, blindness and hearing loss. Solana Beach, Calif.–based ClearPoint Neuro said in a news… […]
  • New Mountain Capital to acquire Flexan
    New Mountain Capital’s ILC Dover today announced that it has reached a definitive agreement to acquire Flexan for an undisclosed amount. Lincolnshire, Ill.–based Flexan is a contract design and manufacturing company specializing in high-precision silicone, rubber and thermoplastic components for the medical device industry. The acquisition will allow both companies to serve a broader client… […]
  • How COVID-19 changed medical device clinical trials forever
    The success of remote clinical trial oversight opens the door to hybrid approaches and creates new possibilities for the future of trials. DeviceTalks Because of the pandemic, virtually overnight, all players involved in medical device clinical trials had to pivot to virtual monitoring to keep trials going. What impact did remote trial oversight have on… […]